Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
Markman
Maurie
M
Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. mmarkman@mdanderson.org
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D055808:Drug Discovery; D009369:Neoplasms / Q000188:drug therapy*; D012107:Research Design / Q000639:trends*
D000970:Antineoplastic Agents